Journal Article

<i>Fez1/Lzts1</i>-deficient mice are more susceptible to <i>N</i>-butyl-<i>N</i>-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis

Raffaele Baffa, Matteo Fassan, Cinzia Sevignani, Andrea Vecchione, Hideshi Ishii, Enrico Giarnieri, Renato V. Iozzo, Leonard G. Gomella and Carlo M. Croce

in Carcinogenesis

Volume 29, issue 4, pages 846-848
Published in print April 2008 | ISSN: 0143-3334
Published online January 2008 | e-ISSN: 1460-2180 | DOI:
Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


FEZ1/LZTS1 is a tumor suppressor gene that is frequently altered in human cancers of different histotypes. We have reported previously that LZTS1 is downregulated in high-grade bladder cancer and that its restoration suppresses tumorigenicity in urothelial carcinoma cells. To further investigate the role of LZTS1 in the development of bladder cancer, we utilized heterozygous and nullizygous Lzts1 mice in a chemically induced carcinogenesis model. Fifty-eight mice consisting of 25 Lzts1+/+, 17 Lzts1+/− and 16 Lzts1−/− were treated with N-butyl-N-(4-hydroxybutil) nitrosamine (BBN). Results showed that there was a significant increase in neoplastic lesions in the Lzts1+/− (82.3%) and Lzts1−/− (93.8%) versus Lzts1+/+ (8.0%) mice after BBN treatment. No difference in cancer incidence between Lzts1+/− and Lzts1−/− was observed. Collectively, these findings indicate that loss of one or both LZTS1 alleles hampers the normal defenses of urothelial cells against carcinogens, favoring bladder cancer development. Therefore, LZTS1 may become an excellent target for gene therapy in advanced bladder carcinoma.

Journal Article.  2226 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.